Drug delivery firm Cure Pharma boosts cannabinoid IP
The California-headquartered firm was granted patents no. 9,044,390 and 9,186,386 from the US Patent and Trademark Office (USPTO), which it said would enable the application of bioactive cannabinoid molecules to dosage forms.
Cure submitted a patent application for its oral film delivery technology – CureFilm – in May last year. The film is administered on the tongue, and designed to deliver several active pharmaceutical ingredients (APIs) without negative interaction.
According to CEO Rob Davidson, the patents will allow Cure to implement accurate and optimal dosing for treatments to target the endocannabinoid system.
Cannabinoid molecules extracted using Cure’s patented technology could also be applied to transdermal, tablets, sublingual and softgel drug delivery technologies, said Davidson.
“We have only seen a glimpse of the potential of cannabinoids, which we are unlocking with our proprietary delivery system,” he added.
Davidson did not disclose which regions the firm is targeting for commercialisation: “We will look to sell cannabinoid products that have been approved by the appropriate authority worldwide.”
Cure Pharma in Israel
Cure said the patents will help advance research at the Israel Institute of Technology – Technion – where it is sponsoring a study.
Under the research agreement, scientists are testing fractionated molecular components from the cannabis plant against various cancer types in vitro and in preclinical models.
In June last year, we reported that Cure had entered a strategic collaboration to test and develop potential cancer therapeutics using a blend of cannabis plant-derived terpenes.
Cannabinoid therapy developer CannaKids and Technion were also involved in the deal, designed to test terpene blend-based treatments on certain subtypes of cancer.
